Literature DB >> 21319864

Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer.

Philip J Saylor, Nancy L Keating, Stephen J Freedland, Matthew R Smith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21319864      PMCID： PMC3671348          DOI： 10.2165/11588930-000000000-00000

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  47 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

Review 2.  AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee.

Authors:  Thomas A Pearson; Steven N Blair; Stephen R Daniels; Robert H Eckel; Joan M Fair; Stephen P Fortmann; Barry A Franklin; Larry B Goldstein; Philip Greenland; Scott M Grundy; Yuling Hong; Nancy Houston Miller; Ronald M Lauer; Ira S Ockene; Ralph L Sacco; James F Sallis; Sidney C Smith; Neil J Stone; Kathryn A Taubert
Journal:  Circulation       Date:  2002-07-16       Impact factor: 29.690

3.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

Authors:  William C Knowler; Elizabeth Barrett-Connor; Sarah E Fowler; Richard F Hamman; John M Lachin; Elizabeth A Walker; David M Nathan
Journal:  N Engl J Med       Date:  2002-02-07       Impact factor: 91.245

4.  Changes in body composition during androgen deprivation therapy for prostate cancer.

Authors:  Matthew R Smith; Joel S Finkelstein; Francis J McGovern; Anthony L Zietman; Mary Anne Fallon; David A Schoenfeld; Philip W Kantoff
Journal:  J Clin Endocrinol Metab       Date:  2002-02       Impact factor: 5.958

5.  Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Authors:  Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

6.  Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.

Authors:  Jason A Efstathiou; Kyounghwa Bae; William U Shipley; Gerald E Hanks; Miljenko V Pilepich; Howard M Sandler; Matthew R Smith
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

7.  The role of primary androgen deprivation therapy in localized prostate cancer.

Authors:  Yu-Ning Wong; Stephen J Freedland; Brian Egleston; Neha Vapiwala; Robert Uzzo; Katrina Armstrong
Journal:  Eur Urol       Date:  2009-04-01       Impact factor: 20.096

8.  Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.

Authors:  Jason A Efstathiou; Kyounghwa Bae; William U Shipley; Gerald E Hanks; Miljenko V Pilepich; Howard M Sandler; Matthew R Smith
Journal:  Eur Urol       Date:  2008-01-15       Impact factor: 20.096

9.  Diagnosis and classification of diabetes mellitus.

Authors: 
Journal:  Diabetes Care       Date:  2009-01       Impact factor: 19.112

10.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

Authors:  Colin Baigent; Lisa Blackwell; Rory Collins; Jonathan Emberson; Jon Godwin; Richard Peto; Julie Buring; Charles Hennekens; Patricia Kearney; Tom Meade; Carlo Patrono; Maria Carla Roncaglioni; Alberto Zanchetti
Journal:  Lancet       Date:  2009-05-30       Impact factor: 79.321
View more
  5 in total

Review 1.  Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association.

Authors:  Umberto Campia; Javid J Moslehi; Laleh Amiri-Kordestani; Ana Barac; Joshua A Beckman; David D Chism; Paul Cohen; John D Groarke; Joerg Herrmann; Carolyn M Reilly; Neal L Weintraub
Journal:  Circulation       Date:  2019-03-26       Impact factor: 29.690

2.  Androgen-deprivation therapy and risk for biliary disease in men with prostate cancer.

Authors:  Philip J Saylor; Matthew R Smith; A James O'Malley; Nancy L Keating
Journal:  Eur Urol       Date:  2013-02-12       Impact factor: 20.096

Review 3.  Higher Incidence of Diabetes in Cancer Patients Compared to Cancer-Free Population Controls: A Systematic Review and Meta-Analysis.

Authors:  Keyi Yang; Zhunzhun Liu; Melissa S Y Thong; Daniela Doege; Volker Arndt
Journal:  Cancers (Basel)       Date:  2022-04-02       Impact factor: 6.639

4.  Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study.

Authors:  E Lin; Hans Garmo; Mieke Van Hemelrijck; Jan Adolfsson; Pär Stattin; Björn Zethelius; Danielle Crawley
Journal:  BMC Cancer       Date:  2021-11-22       Impact factor: 4.430

5.  Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes.

Authors:  E Lin; Hans Garmo; Mieke Van Hemelrijck; Björn Zethelius; Pär Stattin; Emil Hagström; Jan Adolfsson; Danielle Crawley
Journal:  JAMA Netw Open       Date:  2022-08-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.